Necroptosis is a programmed form of necrotic cell death that contributes to neurodegeneration. Unlike apoptosis, necroptosis involves membrane rupture and inflammation, making it a critical pathway in chronic neurological diseases. This regulated necrotic cell death pathway has emerged as a key contributor to neuronal loss in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and multiple sclerosis. The recognition of necroptosis as a distinct pathological mechanism has fundamentally changed our understanding of how neurons die in these conditions, moving beyond the traditional focus on apoptosis to encompass a broader spectrum of regulated necrotic cell death pathways. Understanding the specific contributions of necroptosis to various neurodegenerative conditions has become a major research focus, as it offers potential therapeutic targets that are distinct from other cell death modalities.
Necroptosis is morphologically characterized by:
Unlike apoptotic cells, necroptotic cells release damage-associated molecular patterns (DAMPs) that propagate inflammation to neighboring cells and recruit immune cells to the site of injury[1]. This release of intracellular contents including HMGB1, ATP, and DNA fragments creates a pro-inflammatory microenvironment that can accelerate disease progression in chronic neurodegenerative conditions[2]. The inflammatory cascade triggered by necroptotic cell death distinguishes it from the relatively "silent" cell death seen in apoptosis, where cellular debris is efficiently cleared without triggering significant immune activation. The magnitude of DAMP release in necroptosis can be substantial, as the complete loss of membrane integrity allows for the unrestricted release of cellular components that would remain sequestered in apoptotic bodies.
The discovery of necroptosis dates back to 2005 when Degterev et al. identified necrostatin-1 as a specific inhibitor of necrotic cell death induced by TNF-α[3]. This seminal work established necroptosis as a distinct regulated cell death pathway, separate from both apoptosis and traditional necrosis. Subsequent research has demonstrated the involvement of necroptosis in various disease contexts, including neurodegeneration, cancer, and inflammatory disorders[4]. The original screen that identified necrostatin-1 was designed to find small molecules that could block cell death in the presence of caspase inhibition, a condition that previously was thought to result exclusively in necrotic (unregulated) cell death.
The conceptual framework for necroptosis built upon earlier observations that certain forms of cell death previously classified as "necrotic" actually exhibited features of regulated execution. These included the dependence on specific signaling molecules (RIPK1, RIPK3) and the ability to be inhibited pharmacologically. The field has evolved rapidly, with the identification of MLKL as the final effector in 2012 representing another major milestone[5]. This discovery clarified the mechanistic basis for membrane permeabilization in necroptosis and opened new avenues for therapeutic targeting.
Necroptosis shares some features with both apoptosis and necrosis but is pharmacologically and mechanistically distinct:
| Feature | Apoptosis | Necroptosis | Necrosis |
|---|---|---|---|
| Cell swelling | No | Yes | Yes |
| Membrane integrity | Preserved initially | Disrupted | Disrupted |
| Caspase dependency | Yes | No | No |
| Inflammation | Low | High | High |
| Inhibitors | Z-VAD-FMK | Necrostatin-1 | Limited |
While both necroptosis and pyroptosis are forms of regulated necrotic cell death, they differ in key aspects:
The distinction between these cell death modalities is not merely academic, as it has direct implications for therapeutic targeting. While necrostatin-1 is specific for necroptosis, it does not inhibit pyroptosis, and vice versa for certain inflammasome inhibitors.
The necroptosis pathway is executed by a tripartite complex consisting of:
RIPK1 (Receptor-Interacting Protein Kinase 1)
RIPK3 (Receptor-Interacting Protein Kinase 3)
MLKL (Mixed Lineage Kinase Domain-Like)
The molecular architecture of the necroptotic machinery has been elucidated through cryo-EM studies:
RIPK1 Structure:
RIPK3 Structure:
MLKL Structure:
The structural studies have revealed that MLKL forms a trimer in its active form, with the four-helix bundle domain inserting into the plasma membrane to create pores approximately 10-50 nm in diameter. This size is sufficient to allow cytoplasmic contents to leak while also enabling entry of extracellular ions, ultimately leading to osmotic lysis. The formation of these pores is irreversible, as MLKL remains stably embedded in the membrane even after cell death.
Necroptosis can be activated by multiple stimuli:
Death Receptor Activation
Viral Infection
Endogenous Damage Signals
RIPK1 activity is tightly regulated by ubiquitin chains:
The balance between pro-survival NF-κB signaling and pro-necroptotic signaling often determines the cellular outcome following death receptor activation. In neurons, this balance appears to tilt toward necroptosis under certain pathological conditions, possibly due to altered expression of regulatory proteins or post-translational modifications. The decision point between survival and death appears to hinge on the type of ubiquitin chain attached to RIPK1—linear chains favor survival, while K63-linked chains can promote either outcome depending on additional factors.
Several endogenous inhibitors prevent inadvertent necroptosis activation:
Multiple studies have documented necroptosis activation in Alzheimer's disease brains:
A landmark study by Ofengeim et al. (2017) demonstrated robust activation of RIPK1 in the brains of AD patients, with phosphorylated RIPK1 detected in approximately 30% of neurons in affected regions[16:1]. Importantly, this activation was absent in age-matched control brains, suggesting that necroptosis is not simply a consequence of aging but is pathologically specific to AD. The spatial pattern of necroptosis activation showed remarkable correspondence with the characteristic distribution of neurofibrillary pathology, suggesting a potential relationship between tau pathology and necroptotic signaling.
Amyloid-beta (Aβ) peptides trigger necroptotic cell death through multiple mechanisms:
The connection between Aβ and necroptosis involves both direct effects on neurons and indirect effects through glial activation. Aβ can bind to TNFR1 on neurons, directly initiating the necroptotic cascade without requiring microglial mediator release. However, the microglial TNFα production creates an amplifying loop that accelerates neuronal loss. This dual mechanism suggests that therapeutic interventions targeting either the direct or indirect pathway may provide benefit.
Necroptosis contributes to synaptic loss in AD:
Recent studies using two-photon imaging in animal models have demonstrated that inhibition of necroptosis preserves synaptic density even in the presence of significant amyloid pathology, suggesting that synaptic necroptosis may be an early, targetable event in AD pathogenesis. The involvement of necroptosis in synaptic loss suggests that this pathway may contribute to cognitive decline even before significant neuronal loss occurs.
The inflammatory consequences of necroptosis:
The HMGB1 released from necroptotic neurons is a particularly potent DAMP that binds to TLR4 and RAGE on microglia, triggering a robust inflammatory response that includes additional TNFα release, creating a vicious cycle of neuroinflammation and neuronal death. This feed-forward loop may explain the progressive nature of AD and suggests that interrupting any point in this cycle could potentially slow disease progression.
Preclinical studies have shown promise:
Dopaminergic neurons in the substantia nigra pars compacta are particularly vulnerable to necroptosis:
The selective vulnerability of dopaminergic neurons to necroptosis may relate to their high metabolic demands and the presence of neuromelanin, which can promote oxidative stress and activate innate immune responses. Additionally, the specific expression profile of death receptors and regulatory proteins in these neurons may render them more susceptible to necroptotic activation.
α-Synuclein pathology activates necroptosis:
The interaction between α-synuclein aggregation and necroptosis is bidirectional—while α-synuclein aggregates can trigger necroptosis, necroptotic cell death can promote α-synuclein release and seeding, creating a feed-forward pathological loop. This relationship suggests that therapeutic targeting of necroptosis could potentially break this cycle at multiple points.
Bidirectional relationship with mitochondrial dysfunction:
The involvement of necroptosis in ALS has been confirmed in both sporadic and familial cases, with activated RIPK1 detected in motor neurons and surrounding glia. The non-cell autonomous nature of ALS pathology suggests that necroptosis in supporting cells may contribute to disease progression. Interestingly, some studies suggest that astrocyte necroptosis may be more significant than neuronal necroptosis in ALS, highlighting the importance of non-neuronal cells in disease pathogenesis.
| Compound | Target | Status | Notes |
|---|---|---|---|
| Necrostatin-1 | RIPK1 | Preclinical | First-generation inhibitor[27] |
| Necrostatin-1s | RIPK1 | Improved stability | Better brain penetration |
| GSK'872 | RIPK3 | Preclinical | Blocks RIPK3 activation |
| Compound 1 | MLKL | Early development | Direct MLKL inhibition |
Several approaches are in development:
Rational combinations include:
Necroptosis in neurons triggers microglial activation through DAMP release:
TNF-α from activated microglia can induce necroptosis in neurons:
Anti-inflammatory strategies may interrupt necroptosis-neuroinflammation cycle:
Iannielli et al. Necroptosis in Parkinson's Disease. Cell Death & Disease. 2022. ↩︎
Degterev et al. Identification of Necrostatin-1 as an Inhibitor of Necroptosis. Nature Cell Biology. 2005. ↩︎
Sun et al. MLKL Is the Effector of Necroptosis. Nature Cell Biology. 2012. ↩︎
Weinreb et al. RIPK3 in Neurodegeneration. Brain. 2024. ↩︎
Yuan et al. Necroptosis in ALS Models. Acta Neuropathologica. 2023. ↩︎
Kovacs et al. TNFα-Induced Necroptosis in PD. Journal of Neuroscience. 2022. ↩︎
Hu et al. MLKL Phosphorylation Mechanisms. Molecular Cell. 2023. ↩︎
Orozco et al. RIPK1 Kinase Activity in Disease. Cell Reports. 2024. ↩︎
Meng et al. Necroptosis in Huntington's Disease. Human Molecular Genetics. 2023. ↩︎
Zhang et al. Astrocyte Necroptosis in ALS. Glia. 2024. ↩︎
Pierotti et al. Targeting Necroptosis for Neuroprotection. Trends in Pharmacological Sciences. 2023. ↩︎
Zhao et al. DAMP Release from Necroptotic Cells. Cellular Immunology. 2022. ↩︎
Liu et al. Necroptosis in Multiple Sclerosis. Neurology - Neuroimmunology Neuroinflammation. 2023. ↩︎
Yamada et al. Synaptic Loss via Necroptosis. Journal of Neurochemistry. 2024. ↩︎
Ofengeim et al. RIPK1 in Alzheimer's Disease. Neuron. 2017. ↩︎
Ito et al. RIPK3 Mediates Neuronal Death. Science. 2016. ↩︎ ↩︎
Rai et al. Necroptosis Biomarkers in Neurodegeneration. Alzheimer's & Dementia. 2024. ↩︎
Zhang et al. Therapeutic Targeting of Necroptosis. Pharmacology & Therapeutics. 2023. ↩︎
Li et al. α-Synuclein Induces Necroptosis. Cell Death Discovery. 2023. ↩︎
Moriwaki & Chan. Necroptosis and Inflammation. Trends in Cell Biology. 2024. ↩︎
Chen et al. Microglial Necroptosis in Neuroinflammation. Brain Behavior and Immunity. 2024. ↩︎
Galluzzo et al. RIPK1 Inhibition in ALS Models. Annals of Neurology. 2024. ↩︎
Re et al. Necroptosis in FTD. Acta Neuropathologica Communications. 2024. ↩︎
Viscomi et al. Mitochondrial Dysfunction in Necroptosis. Biochimica et Biophysica Acta - Molecular Basis of Disease. 2023. ↩︎
Karch et al. DAMP Signaling in Neurodegeneration. Journal of Neuroinflammation. 2024. ↩︎
Hanson et al. Necrostatin-1s in Stroke Models. Stroke. 2024. ↩︎
White et al. CSF Biomarkers of Necroptosis. Neurology. 2024. ↩︎
Chen et al. TNFα in Neurodegenerative Diseases. Neuropharmacology. 2023. ↩︎
Momtaz et al. RIPK1 Kinase Domains as Drug Targets. Trends in Pharmacological Sciences. 2024. ↩︎